# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.sec.gov/Archives/edgar/data/1660046/000121390024075787/ea021357401ex99-1_immuron.htm
The focus of this new research agreement is to develop an enhanced formulation of Travelan potentially expanding the coverage o...
Sales Highlights: Global•FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)•June 2024 Quarter AUD$1.3 million up...
-6-K
To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics f...
Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the Company. Durin...
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced p...